SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 8 analyzed stories

Moderna: Now Expect Total Revenue Growth of 15%-25% in 2026, Exceeding Previous Outlook of Up to 10% Growth >MRNA

Moderna now expects total revenue to grow 15%–25% in 2026, compared with its previous outlook for growth of up to 10%. The supplied headline does not explain what is driving the higher forecast.

Published:

Updated:

What happened

Moderna raised its 2026 revenue growth outlook to 15%–25%, from a previous forecast of up to 10%. Third-quarter revenue increased 29% to about $1.3 billion, mainly on stronger international Covid vaccine sales. The company reported a $162 million profit after a loss a year earlier.

Global impact / market context

The higher outlook and return to profit may improve investor views of Moderna’s business. The reported revenue growth was mainly linked to international Covid vaccine sales, so the results do not show whether other sources of revenue also strengthened.

What to watch

  1. Check whether international Covid vaccine sales remain strong, because they were the main stated reason for the outlook increase.
  2. Check Moderna’s next revenue update against its 15%–25% growth outlook, because it will show whether the company is still on track.
  3. Check whether Moderna reports another profit, because the latest $162 million profit followed a loss a year earlier.

Affected assets

  • Moderna, Inc.

Evidence